Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosmanogepix - Basilea Pharmaceutica

Next Previous
X
Search
Drug Profile

Fosmanogepix - Basilea Pharmaceutica

Alternative Names: APX-001; E-1211; E-210; PF-07842805

Latest Information Update: 30 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Developer Amplyx Pharmaceuticals
  • Class Aminopyridines; Antifungals; Antineoplastics; Oxazoles; Phosphates; Small molecules
  • Mechanism of Action GWT1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Coccidioidomycosis; Candidiasis; Mycoses; Cryptococcosis; Aspergillosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Candidaemia
  • Phase II Aspergillosis
  • No development reported Acute myeloid leukaemia; Coccidioidomycosis; Mycoses

Most Recent Events

  • 24 Sep 2024 Pfizer plans a phase III trial in Candidaemia (IV, Infusion) (Oral, Tablet) in December 2022 (NCT05421858)
  • 19 Sep 2024 Basilea enters into agreement with Biomedical Advanced Research and Development Authority (BARDA) to develop Fosmanogepix for Fungal infections
  • 23 Aug 2024 Phase-III clinical trials in Candidaemia (IV) (NCT05421858) (EudraCT-2021-003656-16) (EudraCT-2022-500455-23-00)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top